Accelerating Medicines Partnership (AMP)

The goal of the Accelerating Medicines Partnership (AMP) is to bring together the resources of NIH and industry to improve our understanding of disease pathways and facilitate better selection of targets for treatment. (Read the program description by NIH here.) Collaborations with 10 companies and three NIH Institutes have been established across four major disease areas: Alzheimer's disease, Type 2 diabetes, Rheumatoid Arthritis (RA)/Lupus and Parkinson's disease.

To submit a new concept proposal, complete this form.

Partners

AbbVie 
Biogen
Bristol-Myers Squibb Company
GlaxoSmithKline
Johnson & Johnson
Eli Lilly and Company
Merck & Co., Inc.
Pfizer Inc
Pharmaceutical Research and Manufacturers of America
Sanofi
Takeda Pharmaceuticals International, Inc.

Contacts

David Wholley, M.Phil., Senior Vice President of Research Partnerships, dwholley@fnih.org